Media stories about Vital Therapies (NASDAQ:VTL) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vital Therapies earned a news impact score of 0.01 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.1436230035801 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several research firms recently issued reports on VTL. BidaskClub lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, Raymond James Financial reissued a “buy” rating on shares of Vital Therapies in a research note on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $6.00.
Vital Therapies (VTL) traded down $0.05 during mid-day trading on Thursday, reaching $5.55. The company’s stock had a trading volume of 81,800 shares, compared to its average volume of 149,245. The firm has a market cap of $230.03, a price-to-earnings ratio of -4.14 and a beta of 5.11. Vital Therapies has a 52 week low of $2.25 and a 52 week high of $6.70.
In other news, Director Muneer A. Satter purchased 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were purchased at an average price of $5.48 per share, for a total transaction of $548,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Muneer A. Satter purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were purchased at an average price of $4.77 per share, for a total transaction of $238,500.00. The disclosure for this purchase can be found here. In the last quarter, insiders bought 300,000 shares of company stock worth $1,520,000. Company insiders own 32.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Vital Therapies (VTL) Earning Somewhat Positive News Coverage, Study Shows” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2018/01/18/vital-therapies-vtl-earning-somewhat-positive-news-coverage-study-shows.html.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.